

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of reducing mammalian hair growth which comprises selecting an area of skin on a mammal from which reduced hair growth is desired; and applying to said area of skin, at least once or twice a day over at least two days, a dermatologically acceptable composition comprising an inhibitor of telomerase in an amount effective to reduce hair growth.

2. (Original) The method of claim 1, wherein said inhibitor is ofloxacin.
3. (Original) The method of claim 1, wherein said inhibitor is TMPyP4.
4. (Original) The method of claim 1, wherein said inhibitor is telomerase inhibitor I.
5. (Original) The method of claim 1, wherein said inhibitor is telomerase inhibitor IV.
6. (Original) The method of claim 1, wherein said inhibitor is telomerase inhibitor V.
7. (Original) The method of claim 1, wherein said inhibitor is AZT.
8. (Original) The method of claim 1, wherein said inhibitor is a rubromycin.
9. (Original) The method of claim 1, wherein said inhibitor is a purpuromycin.
10. (Original) The method of claim 1, wherein said inhibitor is 3'-deoxy-2:3'-didehydrothymidine.
11. (Original) The method of claim 1, wherein said inhibitor is dideoxyinosine.
12. (Original) The method of claim 1, wherein said inhibitor is (TTAGGG)3.
13. (Original) The method of claim 1, wherein said inhibitor is levofloxacin.
14. (Original) The method of claim 1, wherein said inhibitor is carbovor.
15. (Original) The method of claim 1, wherein said inhibitor is
ACGTTGAGGGGCATC.
16. (Original) The method of claim 1, wherein said inhibitor is 2-[3-(trifluoromethyl)phenyl]isothiazolin-3-one.
17. (Original) The method of claim 1, wherein said inhibitor is ursodeoxycholic acid.

18. (Original) The method of claim 1, wherein said inhibitor is diazaphilonic acid.
19. (Original) The method of claim 1, wherein said inhibitor is alterperyleneol.
20. (Original) The method of claim 1, wherein said inhibitor is 5-azacytidine.
21. (Original) The method of claim 1, wherein said inhibitor is a 3,4,9,10-perylenetetracarboxylic diimide-based ligand.
22. (Original) The method of claim 1, wherein said inhibitor is 10H-indolo[3,2-b]quinoline.
23. (Original) The method of claim 1, wherein said inhibitor is a 2'-O-McRNA telomerase oligomer.
24. (Original) The method of claim 1, wherein said inhibitor is a 2'-O-alkyl RNA telomerase oligomer.
25. (Original) The method of claim 1, wherein said inhibitor is fomivirsen.
26. (Original) The method of claim 1, wherein said inhibitor is a cationic porphyrin.
27. (Original) The method of claim 1, wherein said inhibitor is diazaphilonic acid.
28. (Original) The method of claim 1, wherein said inhibitor is telomerase inhibitor II.
29. (Original) The method of claim 1, wherein said inhibitor is telomerase inhibitor III.
30. (Original) The method of claim 1, wherein said inhibitor is telomerase inhibitor VI.
31. (Original) The method of claim 1, wherein said inhibitor is telomerase inhibitor VII.
32. (Original) The method of claim 1, wherein said inhibitor is telomerase inhibitor

VIII.

33. (Previously presented) The method of claim 1, wherein the concentration of said inhibitor in said composition is between 0.1% and 30% by weight of the composition.
34. (Original) The method of claim 1, wherein the composition provides a reduction in hair growth of at least 20% when tested in the Golden Syrian Hamster assay.
35. (Original) The method of claim 1, wherein the composition provides a reduction in hair growth of at least 15% when tested in the Golden Syrian Hamster assay.
36. (Original) The method of claim 1, wherein the inhibitor is applied to the skin in an amount of from 10 to 3000 micrograms of said compound per square centimeter of skin.
37. (Original) The method of claim 1, wherein said mammal is a human.

38. (Original) The method of claim 36, wherein said area of skin is on the face of a human.

39. (Original) The method of claim 37, wherein the composition is applied to the area of skin in conjunction with shaving.

40. (Previously presented) The method of claim 37, wherein said area of skin is on a leg of the human.

41. (Previously presented) The method of claim 37, wherein said area of skin is on an arm of the human.

42. (Previously presented) The method of claim 37, wherein said area of skin is in an armpit of the human.

43. (Previously presented) The method of claim 37, wherein said area of skin is on the torso of the human.

44. (Original) The method of claim 1, wherein the composition is applied to an area of skin of a woman with hirsutism.

45. (Original) The method of claim 1, wherein said hair growth comprises androgen stimulated hair growth.

46. (Original) The method of claim 1, wherein the composition further includes a second component that also causes a reduction in hair growth.

47. (Original) The method of claim 1, wherein the inhibitor acts on telomerase.

48. (Original) The method of claim 1, wherein the inhibitor acts on a substrate targeted by telomerase.

Claims 49-51 cancelled.